Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 papers



  Free Subscription


1 BMC Neurol
2 Cephalalgia
1 Headache
1 J Neurol Neurosurg Psychiatry
1 Neurology
1 Rev Neurol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    BMC Neurol

  1. STAUFFER VL, Wang S, Bonner J, Kim B, et al
    Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine.
    BMC Neurol. 2020;20:194.
    PubMed         Abstract available


  2. CHRISTENSEN SL, Munro G, Petersen S, Shabir A, et al
    ATP sensitive potassium (KATP) channel inhibition: A promising new drug target for migraine.
    Cephalalgia. 2020 May 16:333102420925513. doi: 10.1177/0333102420925513.
    PubMed         Abstract available

  3. PAN LH, Wang YF, Lai KL, Chen WT, et al
    Mechanical punctate pain threshold is associated with headache frequency and phase in patients with migraine.
    Cephalalgia. 2020 May 16:333102420925540. doi: 10.1177/0333102420925540.
    PubMed         Abstract available


  4. PELLESI L, Do TP, Ashina H, Ashina M, et al
    Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?
    Headache. 2020 May 21. doi: 10.1111/head.13843.
    PubMed         Abstract available

    J Neurol Neurosurg Psychiatry

  5. DI STEFANO V, Rispoli MG, Pellegrino N, Graziosi A, et al
    Diagnostic and therapeutic aspects of hemiplegic migraine.
    J Neurol Neurosurg Psychiatry. 2020 May 19. pii: jnnp-2020-322850.
    PubMed         Abstract available


  6. PULEDDA F, Schankin C, Goadsby PJ
    Visual snow syndrome: A clinical and phenotypical description of 1,100 cases.
    Neurology. 2020;94:e564-e574.
    PubMed         Abstract available

    Rev Neurol

  7. MAYA-CASALPRIM G, Rudilosso S, Serrano E, Reyes-Leiva D, et al
    [Late-onset migraine equivalent with prolonged aura and altered brain perfusion].
    Rev Neurol. 2020;70:430-432.

Thank you for your interest in scientific medicine.

AMEDEO Migraine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.